Adam J. Townsend is Chief Commercial Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 92,453 shares of APLS, which is worth approximately $3.02 Million. The most recent transaction as insider was on Nov 03, 2022, when has been sold 5,000 shares (Common Stock) at a price of $58.54 per share, resulting in proceeds of $292,700. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 92.5K
0% 3M change
21.0% 12M change
Total Value Held $3.02 Million

Adam J. Townsend Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 03 2022
SELL
Open market or private sale
$292,700 $58.54 p/Share
5,000 Reduced 10.44%
42,907 Common Stock
Nov 03 2022
SELL
Exercise of conversion of derivative security
$75,450 $15.09 p/Share
5,000 Reduced 9.45%
47,907 Common Stock
Oct 03 2022
SELL
Open market or private sale
$333,450 $66.69 p/Share
5,000 Reduced 10.44%
42,907 Common Stock
Oct 03 2022
BUY
Exercise of conversion of derivative security
$75,450 $15.09 p/Share
5,000 Added 9.45%
47,907 Common Stock
Sep 06 2022
SELL
Open market or private sale
$301,900 $60.38 p/Share
5,000 Reduced 10.44%
42,907 Common Stock
Sep 06 2022
BUY
Exercise of conversion of derivative security
$75,450 $15.09 p/Share
5,000 Added 9.45%
47,907 Common Stock
Aug 15 2022
SELL
Open market or private sale
$862,500 $69.0 p/Share
12,500 Reduced 22.56%
42,907 Common Stock
Aug 15 2022
BUY
Exercise of conversion of derivative security
$188,625 $15.09 p/Share
12,500 Added 18.41%
55,407 Common Stock
Aug 11 2022
SELL
Open market or private sale
$837,500 $67.0 p/Share
12,500 Reduced 22.56%
42,907 Common Stock
Aug 11 2022
BUY
Exercise of conversion of derivative security
$188,625 $15.09 p/Share
12,500 Added 18.41%
55,407 Common Stock
Aug 08 2022
SELL
Open market or private sale
$812,500 $65.0 p/Share
12,500 Reduced 22.56%
42,907 Common Stock
Aug 08 2022
BUY
Exercise of conversion of derivative security
$188,625 $15.09 p/Share
12,500 Added 18.41%
55,407 Common Stock
Aug 03 2022
SELL
Open market or private sale
$282,150 $56.43 p/Share
5,000 Reduced 11.65%
37,907 Common Stock
Aug 03 2022
BUY
Exercise of conversion of derivative security
$75,450 $15.09 p/Share
5,000 Added 10.44%
42,907 Common Stock
Jul 11 2022
SELL
Open market or private sale
$242,100 $48.42 p/Share
5,000 Reduced 10.44%
42,907 Common Stock
Jul 11 2022
BUY
Exercise of conversion of derivative security
$75,450 $15.09 p/Share
5,000 Added 9.45%
47,907 Common Stock
Apr 21 2022
SELL
Other acquisition or disposition
-
1,875 Reduced 4.26%
42,138 Common Stock
Feb 10 2022
SELL
Payment of exercise price or tax liability
$42,172 $47.12 p/Share
895 Reduced 1.99%
44,013 Common Stock
Jan 28 2022
SELL
Payment of exercise price or tax liability
$30,872 $38.59 p/Share
800 Reduced 1.75%
44,908 Common Stock
Jan 21 2022
BUY
Grant, award, or other acquisition
-
26,051 Added 36.3%
45,708 Common Stock
Feb 10 2021
SELL
Payment of exercise price or tax liability
$32,831 $47.72 p/Share
688 Reduced 3.52%
18,865 Common Stock
Jan 28 2021
BUY
Grant, award, or other acquisition
-
9,375 Added 32.41%
19,553 Common Stock
AJT

Adam J. Townsend

Chief Commercial Officer
Waltham, MA

Track Institutional and Insider Activities on APLS

Follow Apellis Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS